MEP22608A - Novi ciklični derivati uree, njihovo dobijanje i njihova farmaceutska upotreba kao inhibitora kinaze - Google Patents

Novi ciklični derivati uree, njihovo dobijanje i njihova farmaceutska upotreba kao inhibitora kinaze

Info

Publication number
MEP22608A
MEP22608A MEP-226/08A MEP22608A MEP22608A ME P22608 A MEP22608 A ME P22608A ME P22608 A MEP22608 A ME P22608A ME P22608 A MEP22608 A ME P22608A
Authority
ME
Montenegro
Prior art keywords
nr5r6
cycloalkyl
alkyl
optionally substituted
alkenyl
Prior art date
Application number
MEP-226/08A
Other languages
English (en)
Inventor
Marcel Patek
Anil Nair
Augustin Hittinger
Conception Nemecek
Daniel Bond
Greg Harlow
Herve Bouchard
Jacques Mauger
Jean-Luc Malleron
Mark Palermo
Fahad Al-Obeidi
Thomas Faitg
Hartmut Strobel
Sven Ruf
Kurt Ritter
Youssef El-Ahmad
Dominique Lesuisse
Didier Benard
Original Assignee
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa
Publication of MEP22608A publication Critical patent/MEP22608A/bs

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Obesity (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

Pronalazak se odnosi na nove proizvode formule (I) gdje p predstavlja 0 do 2. R i R1 predstavljaju O ili NH. R2 i R3 posebno predstavljaju vodonik, alkil, alkenil. alkinil, cikloalkil, aril i heteroaril koji su opcionalno supstituisani, ili alternativno R2 i R3 formiraju zajedno sa ugljenikovim atomom za koji su vezani, karbocikličnii ili heterociklični radikal, gdje ovi radikali mogu biti opcionalno supstituisani. A1 predstavlja jednostruku vezu , alkil. alil ili propinil. Y i Y1 posebno predstavljaju H, OCF3, S(0)nCF3, S(0)nAlk, S02CHF2, S02CF2CF3, -0-CHF2. -0-CH2-CF3, SF5 i S02NR5R6, sa R5 i R6 odabranim posebno od vodonika, alkil, alkenil, cikloalkil, cikloalkenil, heterocikloalkil, aril I heteroaril, koji opcionalno mogu biti supstituisani ili alternativno R5 i R6 formiraju zajedno sa N za koji su vezani, heterociklični radikal. A2 predstavlja A1, CO i S02. B2 predstavlja heterociklični radikal opcionalno supstituisan sa jednim ili više supstituenata odabranih od vrednosti za Y2. Y2 posebno predstavlja vodonik, halogen, hidroksi, cijano, alkil, alkoksi, cikloalkil, heterocikloalkil, aril, heteroaril, -O-alkenil, -O-alkinil, -O-cikloalkil, -S(0)n-alkil, -S(0)n-alkenil, -S(0)n-alkinil, -S(0)n-cikloalkil, COOR13, -OCOR13, NR5R6, CONR5R6, S(0)n-NR5R6, -NR10-CO-R13, -NR10-SO2-R13, NH-S02-NR5R6, -NR10-CO-NR5R6, -NR10-CS-NR5R6 ili -NR10-COOR13, gdje svi ovi radikali opcionalno mogu biti supstituisani. n predstavlja ceo broj od 0 do 2, gdje ovi proizvodi mogu biti u bilo kom izomernom obliku ili u obliku soli, kao medicinski proizvodi.
MEP-226/08A 2003-01-31 2004-01-28 Novi ciklični derivati uree, njihovo dobijanje i njihova farmaceutska upotreba kao inhibitora kinaze MEP22608A (bs)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0301098A FR2850652B1 (fr) 2003-01-31 2003-01-31 Nouveaux derives d'uree cyclique, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases
PCT/FR2004/000188 WO2004070050A2 (fr) 2003-01-31 2004-01-28 Derives d'uree cyclique, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases

Publications (1)

Publication Number Publication Date
MEP22608A true MEP22608A (bs) 2010-06-10

Family

ID=32696243

Family Applications (1)

Application Number Title Priority Date Filing Date
MEP-226/08A MEP22608A (bs) 2003-01-31 2004-01-28 Novi ciklični derivati uree, njihovo dobijanje i njihova farmaceutska upotreba kao inhibitora kinaze

Country Status (24)

Country Link
EP (1) EP1599464B1 (bs)
JP (1) JP4604020B2 (bs)
KR (1) KR20050098286A (bs)
CN (1) CN1768054A (bs)
AR (1) AR042936A1 (bs)
AT (1) ATE482207T1 (bs)
AU (1) AU2004209319A1 (bs)
BR (1) BRPI0407091A (bs)
CA (1) CA2513631A1 (bs)
DE (1) DE602004029236D1 (bs)
FR (1) FR2850652B1 (bs)
HR (1) HRP20050679A2 (bs)
MA (1) MA27651A1 (bs)
ME (1) MEP22608A (bs)
MX (1) MXPA05007407A (bs)
NO (1) NO20054006L (bs)
NZ (1) NZ541270A (bs)
PE (1) PE20040808A1 (bs)
PL (1) PL377811A1 (bs)
RS (1) RS20050657A (bs)
RU (1) RU2341523C2 (bs)
TW (1) TW200505898A (bs)
WO (1) WO2004070050A2 (bs)
ZA (1) ZA200505934B (bs)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7491743B2 (en) * 2003-08-29 2009-02-17 President And Fellows Of Harvard College Inhibitors of cellular necrosis
US7592348B2 (en) 2003-12-15 2009-09-22 Schering Corporation Heterocyclic aspartyl protease inhibitors
US7763609B2 (en) 2003-12-15 2010-07-27 Schering Corporation Heterocyclic aspartyl protease inhibitors
US7700603B2 (en) 2003-12-15 2010-04-20 Schering Corporation Heterocyclic aspartyl protease inhibitors
CA2550447A1 (en) 2003-12-19 2005-07-07 The Regents Of The University Of California Methods and materials for assessing prostate cancer therapies
NZ550102A (en) 2004-02-24 2010-10-29 Univ California Methods and materials for assessing prostate cancer therapies and compounds (thiohydantoine derivatives)
EP1621536A1 (en) * 2004-07-27 2006-02-01 Aventis Pharma S.A. Amino cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors
EP1621535A1 (en) * 2004-07-27 2006-02-01 Aventis Pharma S.A. Substituted cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors
ATE541571T1 (de) 2005-05-13 2012-02-15 Univ California Diarylhydantoin-verbindung
US7709517B2 (en) 2005-05-13 2010-05-04 The Regents Of The University Of California Diarylhydantoin compounds
US7709516B2 (en) * 2005-06-17 2010-05-04 Endorecherche, Inc. Helix 12 directed non-steroidal antiandrogens
FR2896503B1 (fr) * 2006-01-23 2012-07-13 Aventis Pharma Sa Nouveaux derives soufres d'uree cyclique, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases
FR2896504B1 (fr) 2006-01-23 2012-07-13 Aventis Pharma Sa Nouveaux derives d'uree cyclique, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases
PT2656841T (pt) * 2006-03-27 2016-09-28 Univ California Modulador do recetor de androgénios para o tratamento de cancro da próstata e doenças associadas ao recetor de androgénios
KR101600230B1 (ko) 2006-03-29 2016-03-04 더 리전트 오브 더 유니버시티 오브 캘리포니아 디아릴티오히단토인 화합물
BRPI0715160A2 (pt) 2006-08-08 2013-06-11 Sanofi Aventis imidazolidina-2,4-dionas substituÍdas por arilamimoaril-alquil-, processo para preparÁ-las, medicamentos compeendendo estes compostos, e seu uso
EP2064191B1 (en) 2006-12-12 2014-06-25 Merck Sharp & Dohme Corp. Aspartyl protease inhibitors
EP2220050A2 (en) 2007-10-26 2010-08-25 The Regents Of The University Of California Diarylhydantoin compounds as androgen receptor modulators
CN102316735A (zh) 2008-12-23 2012-01-11 哈佛大学校长及研究员协会 坏死性凋亡的小分子抑制剂
ES2668380T3 (es) 2010-02-16 2018-05-17 Aragon Pharmaceuticals, Inc. Moduladores de receptores de andrógenos y sus usos
CA2822384C (en) * 2010-12-21 2018-10-30 Cytec Technology Corp. Microdispersions of hydroxamated polymers and methods of making and using them
US8492556B2 (en) * 2011-11-10 2013-07-23 Allergan, Inc. 2,5-Dioxoimidazolidin-1-yl-3-phenylurea derivatives as formyl peptide receptor like-1 (FPRL-1) receptor modulators
SI3305285T1 (sl) 2012-09-26 2021-03-31 Aragon Pharmaceuticals, Inc. Anti-androgeni za zdravljenje proti kastraciji odpornega ne-metastatskega raka
JOP20200097A1 (ar) 2013-01-15 2017-06-16 Aragon Pharmaceuticals Inc معدل مستقبل أندروجين واستخداماته
JP2016514693A (ja) 2013-03-15 2016-05-23 プレジデント アンド フェローズ オブ ハーバード カレッジ ハイブリッド型ネクロトーシス阻害剤
GB201312492D0 (en) * 2013-07-12 2013-08-28 Syngenta Ltd Herbicidal compounds
EA032458B1 (ru) 2014-01-14 2019-05-31 Милленниум Фармасьютикалз, Инк. Гетероарилы и их применение
WO2015108881A1 (en) 2014-01-14 2015-07-23 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
JP2017538712A (ja) 2014-12-11 2017-12-28 プレジデント アンド フェローズ オブ ハーバード カレッジ 細胞壊死の抑制剤及びそれに関連する方法
TWI726969B (zh) 2016-01-11 2021-05-11 比利時商健生藥品公司 用作雄性激素受體拮抗劑之經取代之硫尿囊素衍生物
CN107619388A (zh) * 2016-07-13 2018-01-23 南京天印健华医药科技有限公司 作为fgfr抑制剂的杂环化合物
DK3487851T3 (da) * 2016-07-20 2021-12-20 Novartis Ag Aminopyridinderivater og deres anvendelse som selektive alk-2-inhibitorer
JOP20200076A1 (ar) 2017-10-16 2020-04-30 Aragon Pharmaceuticals Inc مضادات أندروجين لعلاج سرطان البروستاتا غير النقيلي المقاوم للاستئصال
EP3705474A4 (en) * 2017-10-31 2021-06-09 Pelemed Co., Ltd. PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF ACUTE MYELOIC LEUKEMIA OR METASTATIC BREAST CANCER

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2329276A1 (fr) * 1975-10-29 1977-05-27 Roussel Uclaf Nouvelles imidazolidines substituees, procede de preparation, application comme medicament et compositions les renfermant
DE4228717A1 (de) * 1992-08-28 1994-03-03 Cassella Ag Imidazolidin-Derivate
DE19540027A1 (de) * 1995-10-27 1997-04-30 Gruenenthal Gmbh Substituierte Imidazolidin-2,4-dion-Verbindungen als pharmazeutische Wirkstoffe
CA2278547A1 (en) * 1997-03-03 1998-09-11 Boehringer Ingelheim Pharmaceuticals, Inc. Small molecules useful in the treatment of inflammatory disease
DE19732928C2 (de) * 1997-07-31 2000-05-18 Gruenenthal Gmbh Verwendung substituierter Imidazolidin-2,4-dion-Verbindungen als Schmerzmittel
FR2796945B1 (fr) * 1999-07-30 2002-06-28 Sod Conseils Rech Applic Nouveaux derives d'hydantoines, de thiohydantoines, de pyrimidinediones et de thioxopyrimidinones, leurs procedes de preparation et leur application a titre de medicaments
PT1284973E (pt) * 2000-05-31 2007-08-17 Tanabe Seiyaku Co ''inibidores de adesão celular mediada por alfa l beta 2''
US7476685B2 (en) * 2002-05-16 2009-01-13 Merial Limited Pyridine carboxamide derivatives and their use as pesticides

Also Published As

Publication number Publication date
FR2850652A1 (fr) 2004-08-06
AU2004209319A1 (en) 2004-08-19
WO2004070050A2 (fr) 2004-08-19
EP1599464A2 (fr) 2005-11-30
NO20054006L (no) 2005-10-13
HRP20050679A2 (en) 2006-12-31
WO2004070050A3 (fr) 2005-02-17
FR2850652B1 (fr) 2008-05-30
CN1768054A (zh) 2006-05-03
MXPA05007407A (es) 2005-09-12
RS20050657A (en) 2007-06-04
PL377811A1 (pl) 2006-02-20
EP1599464B1 (fr) 2010-09-22
RU2005127335A (ru) 2006-09-10
ZA200505934B (en) 2007-06-27
NZ541270A (en) 2008-11-28
AR042936A1 (es) 2005-07-06
KR20050098286A (ko) 2005-10-11
ATE482207T1 (de) 2010-10-15
NO20054006D0 (no) 2005-08-29
JP2006517569A (ja) 2006-07-27
CA2513631A1 (fr) 2004-08-19
JP4604020B2 (ja) 2010-12-22
MA27651A1 (fr) 2005-12-01
RU2341523C2 (ru) 2008-12-20
TW200505898A (en) 2005-02-16
BRPI0407091A (pt) 2006-01-24
DE602004029236D1 (de) 2010-11-04
PE20040808A1 (es) 2004-12-31

Similar Documents

Publication Publication Date Title
MEP22608A (bs) Novi ciklični derivati uree, njihovo dobijanje i njihova farmaceutska upotreba kao inhibitora kinaze
TW200617004A (en) Novel heterocycle-substituted cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors
NO20052993L (no) 4,5-diaryltiazolderivater som CB-1 ligander.
MXPA03010129A (es) N-aroilaminas-ciclicas.
NO20082976L (no) Svovelholdige cykliske ureaderivater, fremstilling derav og farmasoytisk anvendelse derav som kinaseinhibitorer
NO20063780L (no) Fremgangsmate for fremstilling av 2-aminitiazol-5-aromatisk karboksamid som kinase inhibitorer.
HUP0500339A2 (hu) GSK3-mal kapcsolatos állapotok kezelésére használható aril-aminok, eljárás előállításukra, az ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
NO20080456L (no) Nye 2,4-dianilinopyrimidinderivater, fremstilling derav og deres anvendelse som medikamenter, farmasoytiske sammensetninger og, spesielt, som IKK inhibitorer
NO20061406L (no) Organiske forbindelser
SE0104140D0 (sv) Novel Compounds
CY1106969T1 (el) Αναστολεις dpp-iv
NO20065830L (no) Substituerte 2-kinolyloksazoler som er anvendbare som PDE4-inhibitorer.
ME00590A (bs) Derivati n-(aminoheteroaril)-1h-indol-2-karboksamida njihovo dobijanje i terapeutska primjena
WO2002089800A3 (en) N-aroyl cyclic amine derivatives as orexin receptor antagonists
WO2004069793A3 (en) Novel 2-substituted cyclic amines as calcium sensing receptor modulators
DE602005012811D1 (de) Triazolonderivate als mmp-inhibitoren zur behandlung von asthma und copd
TWI256953B (en) Pyrimidine compounds
ATE507229T1 (de) Cucurbiturilderivate, die in wasser und organischen lösungsmitteln löslich sind, verfahren zu deren herstellung, verfahren zu deren trennung und deren anwendung
DE60142934D1 (de) Pharmazeutische dopamin-glykokonjugat-zusammensetzungen und verfahren zu deren herstellung
TW200738667A (en) Preparation method for dioxan-2-ylalkylcarbamate derivatives and intermediate thereof
DK1517890T3 (da) Kationisk substituerede diphenylazetidinoner, fremgangsmåde til deres fremstilling, lægemidler indeholdende disse forbindelser og deres anvendelse
NO20061045L (no) Imidazolderivater
MXPA05007848A (es) Derivados de arilalquilcarbamatos, su preparacion y su aplicacion en terapeutica.
NO20062202L (no) Amidometylsubstituerte 2-(4-sulfonylamino)-3-hydroksy-3,4-dihydro-2H-kromen-6-yl-derivater, fremgangsmate og mellomprodukter for deres fremstilling, og legemidler som inneholder disse forbindelsene
MXPA05007519A (es) Nuevos derivados de la purina, su procedimiento de preparacion, su aplicacion como medicamentos, composiciones farmaceuticas y nueva utilizacion.